{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:06:17Z","timestamp":1789625177784,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020594","name":"Israel Institute for Biological Research","doi-asserted-by":"publisher","award":["SB-208"],"award-info":[{"award-number":["SB-208"]}],"id":[{"id":"10.13039\/501100020594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than seven million deaths worldwide. To reduce viral spread, the Israel Institute for Biological Research (IIBR) developed and produced a new rVSV-SARS-CoV-2-S vaccine candidate (BriLife\u00ae) based on a platform of a genetically engineered vesicular stomatitis virus (VSV) vector that expresses the spike protein of SARS-CoV-2 instead of the VSV-G protein on the virus surface. Quantifying the virus titer to evaluate vaccine potency requires a reliable validated assay that meets all the stringent pharmacopeial requirements of a bioanalytical method. Here, for the first time, we present the development and extensive validation of a quantitative plaque assay using Vero E6 cells for the determination of the concentration of the rVSV-SARS-CoV-2-S viral vector. Three different vaccine preparations with varying titers (DP_low, DP_high, and QC sample) were tested according to a strict validation protocol. The newly developed plaque assay was found to be highly specific, accurate, precise, and robust. The mean deviations from the predetermined titers for the DP_low, DP_high, and QC preparations were 0.01, 0.02, and 0.09 log10, respectively. Moreover, the mean %CV values for intra-assay precision were 18.7%, 12.0%, and 6.0%, respectively. The virus titers did not deviate from the established values between cell passages 5 and 19, and no correlation was found between titer and passage. The validation results presented herein indicate that the newly developed plaque assay can be used to determine the concentration of the BriLife\u00ae vaccine, suggesting that the current protocol is a reliable methodology for validating plaque assays for other viral vaccines.<\/jats:p>","DOI":"10.3390\/vaccines12040374","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T05:44:36Z","timestamp":1711950276000},"page":"374","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and Validation of a Plaque Assay to Determine the Titer of a Recombinant Live-Attenuated Viral Vaccine for SARS-CoV-2"],"prefix":"10.3390","volume":"12","author":[{"given":"Einat","family":"Toister","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilach","family":"Cherry","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"},{"name":"Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Lupu","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arik","family":"Monash","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Dor","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilach","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meni","family":"Girshengorn","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niva","family":"Natan","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Shmaya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9312-734X","authenticated-orcid":false,"given":"Eyal","family":"Epstein","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Adar","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-4901","authenticated-orcid":false,"given":"Ran","family":"Zichel","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Ophir","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"},{"name":"Department of Microbiology, Cornell University, Ithaca, NY 14850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Diamant","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, February 23). WHO COVID-19 Dashboard. Available online: https:\/\/data.who.int\/dashboards\/covid19\/cases."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cohen, N., Simon, I., Hazan, O., Tal, A., Tzadok, H., Levin, L., Girshengorn, M., Mimran, L.C., Natan, N., and Baruhi, T. (2024). Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel\u00ae macrocarriers. Front. Bioeng. Biotechnol., 12.","DOI":"10.3389\/fbioe.2024.1333548"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lerer, E., Oren, Z., Kafri, Y., Adar, Y., Toister, E., Cherry, L., Lupu, E., Monash, A., Levy, R., and Dor, E. (2021). Highly Efficient Purification of Recombinant VSV-\u2206G-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography. BioTech, 10.","DOI":"10.3390\/biotech10040022"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1016\/j.vaccine.2021.10.045","article-title":"Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate","volume":"39","author":"Makovitzki","year":"2021","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00204-022-03302-5","article-title":"rVSV-\u0394G-SARS-CoV-2-S vaccine: Repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits","volume":"96","author":"Rosner","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-\u2206G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Tamir","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_7","unstructured":"Centers for Disease Control and Prevention (2024, February 23). Ebola Vaccine: Information about ERVEBO\u00ae, Available online: https:\/\/www.cdc.gov\/vhf\/ebola\/clinicians\/vaccine\/index.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0065-3527(08)60689-2","article-title":"The Plaque Assay of Animal Viruses","volume":"Volume 8","author":"Smith","year":"1962","journal-title":"Advances in Virus Research"},{"key":"ref_11","unstructured":"European Directorate for the Quality of Medicines and Healthcare (2020). Smallpox Vaccine (Live), European Pharmacopoeia. [10th ed.]."},{"key":"ref_12","unstructured":"European Medicines Agency (1995). ICH Topic Q 2 (R1)\u2014Validation of Analytical Procedure: Text and Methodology."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-021-00317-4","article-title":"Considerations for bioanalytical characterization and batch release of COVID-19 vaccines","volume":"6","author":"Sanyal","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yahalom-Ronen, Y., Erez, N., Fisher, M., Tamir, H., Politi, B., Achdout, H., Melamed, S., Glinert, I., Weiss, S., and Cohen-Gihon, I. (2022). Neutralization of SARS-CoV-2 Variants by rVSV-&Delta;G-Spike-Elicited Human Sera. Vaccines, 10.","DOI":"10.3390\/vaccines10020291"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1128\/am.19.2.360-366.1970","article-title":"Plaque formation by mumps virus and inhibition by antiserum","volume":"19","author":"Flanagan","year":"1970","journal-title":"Appl. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jviromet.2012.09.026","article-title":"Assessment of plaque assay methods for alphaviruses","volume":"187","author":"Juarez","year":"2013","journal-title":"J. Virol. Methods"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0092-1157(80)80037-0","article-title":"A simplified plaque assay system for measles virus","volume":"8","author":"Mann","year":"1980","journal-title":"J. Biol. Stand."},{"key":"ref_18","first-page":"314","article-title":"A plaque method for rubella virus assay","volume":"89","author":"Rozee","year":"1963","journal-title":"Can. Med. Assoc. J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mendoza, E.J., Manguiat, K., Wood, H., and Drebot, M. (2020). Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. Curr. Protoc. Microbiol., 57.","DOI":"10.1002\/cpmc.105"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jviromet.2005.05.027","article-title":"Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera","volume":"130","author":"Eyal","year":"2005","journal-title":"J. Virol. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"McCracken, R., Al-Nazal, N., Whitmer, T., Yi, S., Wagner, J.M., Hebert, C.G., Lowry, M.J., Hayes, P.R., Schneider, J.W., and Przybycien, T.M. (2022). Rapid In-Process Measurement of Live Virus Vaccine Potency Using Laser Force Cytology: Paving the Way for Rapid Vaccine Development. Vaccines, 10.","DOI":"10.3390\/vaccines10101589"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1038\/s41598-021-86688-z","article-title":"Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO","volume":"11","author":"Ricci","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Shurtleff, A.C., Bloomfield, H.A., Mort, S., Orr, S.A., Audet, B., Whitaker, T., Richards, M.J., and Bavari, S. (2016). Validation of the Filovirus Plaque Assay for Use in Preclinical Studies. Viruses, 8.","DOI":"10.3390\/v8040113"},{"key":"ref_24","unstructured":"United States Pharmacopeia (2007). Chapter 1223 Validation of Alternative Microbiological Methods, USP."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/4\/374\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:22:06Z","timestamp":1760106126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/4\/374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["vaccines12040374"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12040374","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}